Ferritin is an iron storage protein considered also as an acute phase reactant with high levels in various inflammatory conditions. Recently, a plausible role for ferritin in the pathogenesis of immune-mediated and especially autoimmune diseases has been suggested. However, the link between ferritin and the antiphospholipid syndrome (APS) has been rarely explored. Therefore, in the current study we evaluated ferritin levels and their correlation to clinical and serological manifestations in patients with APS. We further analyzed ferritin levels among patients with the catastrophic variant of APS (cAPS).
Methods
Ferritin levels were determined in serum samples of 176 APS patients and 98 matched healthy controls according to age and sex (LIAISON, DiaSorin, Italy). APS samples were further analyzed for antiphospholipid (anti-cardiolipin, anti- beta-2-glycoprotein, lupus anticoagulant) and anti-infectious antibodies (CMV, EBV, rubella, toxoplasma, HBV) (LIAISON, DiaSorin, Italy). Clinical, serological and demographic manifestations were recorded. An additional analysis of ferritin levels among 14 patients with cAPS was performed.
Results
Hyperferritinemia was present in 9% vs. 0% of APS patients and controls, respectively (p < 0.001). Among patients with APS, ferritin levels correlated with venous thrombosis, cardiac, neurological, and hematological manifestations and the presence of anti-CMV-IgM antibodies. Hyperferritinemia was present in 71% of cAPS patients, and ferritin levels among this subgroup were significantly higher compared with APS-non-cAPS patients (816 ± 847 ng/ml vs. 120 ± 230 ng/ml, p < 0.001).
Conclusions
Herein, we found that hyperferritinemia correlates with the presence of APS, its clinical manifestations and specifically with the catastrophic variant of this disease. Hyperferritinemia was also linked with anti-CMV antibodies among patients with APS. These associations allude to a pathogenic role of ferritin in the pathogenesis of APS, and the plausible role of ferritin as a marker of ensuing cAPS, although further studies are needed to elucidate these associations.
LinertWJamesonGN. Redox reactions of neurotransmitters possibly involved in the progression of Parkinson's disease. J Inorg Biochem2000; 79: 319–326.
6.
WeinsteinREBondBHSilberbergBK. Tissue ferritin concentration in carcinoma of the breast. Cancer1982; 50: 2406–2409.
7.
RecalcatiSInvernizziPArosioPCairoG. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. J Autoimmun2008; 30: 84–89.
8.
BroxmeyerHEBognackiJDornerMHde SousaM. Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med1981; 153: 1426–1444.
9.
HannHWStahlhutMWLeeSLondonWTHannRS. Effects of isoferritins on human granulocytes. Cancer1989; 63: 2492–2496.
10.
MorikawaKOsekoFMorikawaS. H- and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood1994; 83: 737–743.
11.
AtteritanoMDavidABagnatoG. Haemophagocytic syndrome in rheumatic patients. A systematic review. Eur Rev Med Pharmacol Sci2012; 16: 1414–1424.
12.
UppalSSAl-MutairiMHayatSAbrahamMMalaviyaA. Ten years of clinical experience with adult onset Still's disease: Is the outcome improving?Clin Rheumatol2007; 26: 1055–1060.
13.
OrbachHZandman-GoddardGAmitalH. Novel biomarkers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci2007; 1109: 385–400.
14.
BlakeDRBaconPAEasthamEJBrighamK. Synovial fluid ferritin in rheumatoid arthritis. BMJ1980; 281: 715–716.
15.
YildirimKKarataySMelikogluMAGureserGUgurMSenelK. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci2004; 34: 423–426.
16.
SfagosCMakisACChaidosA. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler2005; 11: 272–275.
17.
Da CostaRSzyper-KravitzMSzekaneczZ. Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J2011; 13: 91–95.
18.
BeyanEBeyanCDemirezerAErtugrulEUzunerA. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol2003; 32: 225–228.
19.
LimMKLeeCKJuYS. Serum ferritin as a serologic marker of activity in systemic lupus erythematosus. Rheumatol Int2001; 20: 89–93.
20.
Zandman-GoddardGOrbachHAgmon-LevinN. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol2011; 44: 23–30.
21.
Zandman-GoddardGShoenfeldY. Ferritin in autoimmune diseases. Autoimmun Rev2007; 6: 457–463.
22.
MewarDMooreDJYoung-MinS. Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. Arthritis Rheum2005; 52: 3868–3872.
23.
BaerleckenNTLinnemannAGrossWL. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis2012; 71: 943–947.
24.
Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71: 943–947.
25.
PierangeliSSChenPPRaschiE. Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenic mechanisms. Semin Thromb Hemost2008; 34: 236–250.
26.
ComarmondCCacoubP. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmun Rev2013; 12: 752–757.
27.
ShoenfeldY. APS – more systemic disease than SLE. Clin Rev Allergy Immunol2007; 32: 129–130.
28.
CerveraR. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep2010; 12: 70–76.
29.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
30.
Agmon-LevinNKivitySTzioufasAG. Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjögren's syndrome. J Autoimmun2012; 39: 234–239.
31.
de CarvalhoJFPereiraRMShoenfeldY. The mosaic of autoimmunity: The role of environmental factors. Front Biosci (Elite Ed)2009; 1: 501–509.
de CarvalhoJFPereiraRMShoenfeldY. Current knowledge regarding Asherson's syndrome. Expert Rev Clin Immunol2009; 5: 587–591.
34.
RuddellRGHoang-LeDBarwoodJM. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology2009; 49: 887–900.
Agmon-LevinNBlankMZandman-GoddardG. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis2011; 70: 145–150.
37.
Ortega-HernandezODAgmon-LevinNBlankMAshersonRAShoenfeldY. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. J Autoimmun2009; 32: 1–6.
38.
ToubiEShoenfeldY. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol2007; 32: 138–144.
39.
MatsuuraELopezLR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?Clin Dev Immunol2004; 11: 103–111.
40.
SolteszPSzekaneczZKissEShoenfeldY. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev2007; 6: 379–386.
CimazRMeroniPLShoenfeldY. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus2006; 15: 191–197.
44.
SannaGD'CruzDCuadradoMJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am2006; 32: 465–490.
45.
CheepsunthornPPalmerCMenziesSRobertsRLConnorJR. Hypoxic/ischemic insult alters ferritin expression and myelination in neonatal rat brains. Journal Comp Neurol2001; 431: 382–396.
46.
QiYDawsonG. Hypoxia specifically and reversibly induces the synthesis of ferritin in oligodendrocytes and human oligodendrogliomas. J Neurochem1994; 6: 1485–1490.
47.
QiYJamindarTMDawsonG. Hypoxia alters iron homeostasis and induces ferritin synthesis in oligodendrocytes. J Neurochem1995; 64: 2458–2464.
48.
GorterJAMesquitaARvan VlietEAda SilvaFHAronicaE. Increased expression of ferritin, an iron-storage protein, in specific regions of the parahippocampal cortex of epileptic rats. Epilepsia2005; 46: 1371–1379.
49.
HendriksenHDatsonNAGhijsenWE. Altered hippocampal gene expression prior to the onset of spontaneous seizures in the rat post-status epilepticus model. Eur J Neurosci2001; 14: 1475–1484.
50.
TanneDHassin-BaerS. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep2001; 3: 286–292.
51.
KivitySAgmon-LevinNBlankMShoenfeldY. Infections and autoimmunity – friends or foes?Trends Immunol2009; 30: 409–414.
52.
AshersonRAShoenfeldY. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome – molecular mimicry?J Rheumatol2000; 27: 12–14.
53.
BlankMEisentinMAshersonRACerveraRShoenfeldYThe infectious origin of the antiphospholipid syndrome. In: RoseYSNR (eds). Infection and autoimmunity, Amsterdam: Elsevier, 2004, pp. 473–490.
54.
CerveraRBucciarelliSEspinosaG. Catastrophic antiphospholipid syndrome: Lessons from the “CAPS Registry” – a tribute to the late Josep Font. Ann N Y Acad Sci2007; 1108: 448–456.
55.
Cruz-TapiasPBlankMAnayaJMShoenfeldY. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol2012; 24: 389–393.
56.
EspinosaGBucciarelliSAshersonRACerveraR. Morbidity and mortality in the catastrophic antiphospholipid syndrome: Pathophysiology, causes of death, and prognostic factors. Semin Thromb Hemost2008; 34: 290–294.
57.
ShoenfeldYBlankMKrauseI. The relationship of antiphospholipid antibodies to infections – do they bind to infecting agents or may they even be induced by them?Clin Exp Rheumatol2000; 18: 431–432.
58.
BarzilaiOShererYRamMIzhakyDAnayaJMShoenfeldY. Epstein–Barr virus and cytomegalovirus in autoimmune diseases: Are they truly notorious? A preliminary report. Ann N Y Acad Sci2007; 1108: 567–577.
59.
HojnikMGilburdBZiporenL. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: Analysis of anticardiolipin antibodies in leprosy. Lupus1994; 3: 515–521.
60.
LunardiCTinazziEBasonCDolcinoMCorrocherRPuccettiA. Human parvovirus B19 infection and autoimmunity. Autoimmun Rev2008; 8: 116–120.
ZingerHShererYGoddardG. Common infectious agents prevalence in antiphospholipid syndrome. Lupus2009; 18: 1149–1153.
63.
ArnsonYAmitalHGuiducciS. The role of infections in the immunopathogensis of systemic sclerosis – evidence from serological studies. Ann N Y Acad Sci2009; 1173: 627–632.
64.
CriscuoliVRizzutoMRCottoneM. Cytomegalovirus and inflammatory bowel disease: Is there a link?World J Gastroenterol2006; 12: 4813–4818.
65.
FilippiCvon HerrathM. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol2005; 233: 125–132.
66.
SekigawaINawataMSetaNYamadaMIidaNHashimotoH. Cytomegalovirus infection in patients with systemic lupus erythematosus. Clin Exp Rheumatol2002; 20: 559–564.
67.
GarciaPCLonghiFBrancoRGPivaJPLacksDTaskerRC. Ferritin levels in children with severe sepsis and septic shock. Acta paediatr2007; 96: 1829–1831.
68.
MollerHJMoestrupSKWeisN. Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med2006; 34: 2561–2566.
69.
PatterilMVDavey-QuinnAPGedneyJAMurdochSDBellamyMC. Functional iron deficiency, infection and systemic inflammatory response syndrome in critical illness. Anaesth Intensive Care2001; 29: 473–478.
